Month: April 2024

MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032. “RepaGyn® and Proktis-M® have been part of our product portfolio since we first launched these products in Canada in 2014,” commented René Goehrum, President and CEO of BioSyent. “We are pleased to continue to offer these trusted products to Canadian patients over the long-term and we look forward to their continued growth.” About RepaGyn® RepaGyn® is an innovative vaginal suppository recommended for relieving...

San Diego, CA, April 15, 2024 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), a leading innovator of payment transaction solutions leveraging proprietary blockchain ledger and electronic token technology for the diverse international markets, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by RYVYL. In addition, RYVYL intends to grant the underwriter in the offering a 45-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may...

Company Reconfirms 2024 Full Year GuidanceAnnounces Preliminary Q1 2024 RevenueCompany to Host Investor Day in Fall 2024 MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) — Gildan Activewear Inc. (GIL; TSX and NYSE) today announced that its President and CEO, Vince Tyra has unveiled his key focus strategic priorities. Concurrently, the Company also reconfirmed its 2024 full year guidance and announced preliminary Q1 revenue. Furthermore, the Company intends to hold an Investor Day in the Fall of 2024 to provide a comprehensive strategic plan. Reflecting on his first 90 days, Vince Tyra said, “I’m excited to be leading Gildan at this pivotal time. Having completed 90 days at the helm of Gildan, I wanted to share with you my key focus strategic priorities and articulate how we can leverage our strengths and accelerate value creation for...

ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement with Syntone Ventures, LLC, an existing stockholder, for upfront gross proceeds of approximately $5.0 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before deducting offering expenses. In addition, Outlook Therapeutics has the potential to receive additional gross proceeds of up to $8 million upon the full cash exercise of the warrants issued in the private placement, before deducting offering expenses. About the Private Placement Pursuant...

Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treatment-naïve EGFR exon 20 NSCLC Expect to report updated Phase 1b data in the first half of 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the completion of the dose escalation portion of the Phase 1b trial of ORIC-114 in patients with advanced solid tumors with EGFR and HER2 exon 20 alterations or HER2 amplifications. Based upon these data,...

DALLAS, April 15, 2024 (GLOBE NEWSWIRE) — Beneficient (Nasdaq: BENF) (together with its affiliates, “Ben” or the “Company”), a technology-enabled platform focused on providing liquidity and related trust and custody services to holders of alternative assets through its proprietary online portal, AltAccess, today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 2:00 p.m. Pacific Daylight Time.  At the showcase, Beneficient executives will present in-depth information about its market opportunity and the business model the Company is employing to serve the unmet custody and liquidity needs of investors in alternative assets. To access the live presentation, please use the following information: Date: Wednesday, May 1, 2024Time: 2:00 p.m. Pacific Daylight TimeWebcast: https://shareholders.trustben.com   Management...

MONTREAL, April 15, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has mailed its 2024 management proxy circular to shareholders in connection with its virtual annual meeting of shareholders to be held on May 9, 2024, at 10:00 a.m. ET. Shareholders are encouraged to vote their shares for the proposals contained in the circular and to attend the annual meeting, which can be accessed through the following link: https://meetnow.global/M7MFS6Y.  At the meeting, shareholders will be asked to vote for the following individuals as directors of the Company for the ensuing year:Joseph Arena; Frank Holler; Paul Lévesque; Andrew Molson Dawn...